FILING ANALYSIS · TUESDAY, NOVEMBER 3
PRECISION BIOSCIENCES INC DTIL — 8-K: Results of Operations and Financial Condition
neutral
The company reported a cash balance of $108 million, expected to provide runway through 2028, and announced progress in its clinical trials, including a late-breaking oral presentation for the ELIMINATE-B trial and the dosing of the first patient in the FUNCTION-DMD study, but no quantified surprises were disclosed.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →